References
- Boyle BA, Jayaweera J, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008;9:164-76
- Kress KD. HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61(suppl 3):S3-S14
- Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Value in Health 2011;14:657-64
- Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356
- Smith CJ, Lampe FC, Youle M, et al. Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART). J Int AIDS Soc 2008;11(Suppl 1):O37
- Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 27, 2012; 1-240. http://aidsinfo.nih.gov/guidelines. Accessed April 2012
- Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. 2012. http://www.fda.gov. Accessed January 2013
- Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged release capsules. HIV Medicine 2005;6:185-90
- Cohen C, Molina J, Cassetti I, et al. Pooled week 96 efficacy, resistance, and safety results from the double-blind, randomised, phase III trials comparing rilpivirin (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Poster Presentation at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17–20, 2011; Rome, Italy
- Cohen C, Molina JM, Cahn P, et al. Pooled week 48 safety and efficacy results from the echo and thrive phase III trials comparing TMC278 vs EFV in treatment-naive, HIV-infected patients. Oral Presentation 0432. Presented at: The XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria
- Bristol Myers Squibb Co. Atripla package insert. Plainsboro, NJ. June 2012
- Gilead Sciences. Complera package insert. Foster City, CA. Revised August 2012
- Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009;57:1-134
- Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7
- Sonnenberg FA, Beck JR, Markov models in medical decision making. Medical Decision Making 1993, p 329
- World Health Organization (WHO). Guide to cost-effectiveness analysis. Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. Geneva, Switzerland: WHO; 2013; 45-8
- Microsoft. Microsoft Excel. Redmond, Washington: Microsoft, 2010. Computer Software
- Sanders GD, Bayoumi AM, Sundaram S, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85
- Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
- Bishai D, Haberlen S, Spacek L, et al. Comparing the cost-effectiveness of first-line HAART regimens. Poster P10.4/06 presented at 11th European AIDS Conference (EACS), October 24–27, 2007; Madrid, Spain
- World Health Organization (WHO). HIV drug resistance fact sheet. April 2011; www.who.int/hiv/. Accessed January 2012